FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBio-Rad Laboratories, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BIO
Bio-Rad Laboratories, Inc. Stock AnalysisComprehensive stock analysis for Bio-Rad Laboratories, Inc. (BIO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBIO
BIO
Bio-Rad Laboratories, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BIO
  1. Home
  2. Stocks
  3. Bio-Rad Laboratories, Inc.
BI

Bio-Rad Laboratories, Inc.

🇺🇸BIO•NYSE
BI

Bio-Rad Laboratories, Inc.

🇺🇸BIO•NYSE
Market cap
$9.95B
P/E ratio
9.69

Your view on BIO

Mkt Cap
$9.95B
P/E
9.69
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Bio-Rad Laboratories, Inc.

Industry
Medical - Devices
Sector
Healthcare
CEO
Norman D. Schwartz
Headquarters
US
Industry
Medical - Devices
Sector
Healthcare
CEO
Norman D. Schwartz
Headquarters
US
Description

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments.

The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety.

This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories.

The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market.

It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Bio-Rad Laboratories, Inc. from FRC's valuation model, read against the market price. BIO last traded at $370.17, 9.7× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Bio-Rad Laboratories, Inc.. Starting points for Bio-Rad Laboratories, Inc.: P/E 9.7, EPS $38.20, beta 1.06 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Bio-Rad Laboratories, Inc.. Trailing twelve-month EPS for Bio-Rad Laboratories, Inc. stands at $38.20. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Bio-Rad Laboratories, Inc.. Bio-Rad Laboratories, Inc. has reported as a listed company since 1980. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold BIO12 companies
More Medical - Devices companies
TickerTypeCompanySectorExchangeMkt cap
NWCINewCardio, Inc.HealthcareOTC$3,315
NXLNexalin Technology, Inc.HealthcareNASDAQ$1.8M
OCPNFOlympus CorporationHealthcareOTC$10.6B
ODYYOdyssey Health, Inc.HealthcareOTC$5.5M
OFIXOrthofix Medical Inc.HealthcareNASDAQ$269.4M
OLYMYOlympus CorporationHealthcareOTC$10.3B
OMOutset Medical, Inc.HealthcareNASDAQ$57.3M
OSL.AXOncoSil Medical LtdHealthcareASX—
OSSFFEmbla Medical hf.HealthcareOTC$2.1B
OSSUYEmbla Medical hf.HealthcareOTC$1.9B
OWLTOwlet, Inc.HealthcareNYSE$107.2M
PACBPacific Biosciences of California, Inc.HealthcareNASDAQ$571.4M
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Bio-Rad Laboratories, Inc., and how their positions are changing. At a $9.95B market value, institutional positions materially move Bio-Rad Laboratories, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Bio-Rad Laboratories, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Bio-Rad Laboratories, Inc.. Bio-Rad Laboratories, Inc. is a $9.95B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Bio-Rad Laboratories, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Bio-Rad Laboratories, Inc.. Coverage tracks Bio-Rad Laboratories, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Bio-Rad Laboratories, Inc.

BIO AnalysisGood
Past
4
Growth
2
Health
4
Profit
2
Value
4

News

Latest Market News